eXoZymes Awarded $2 Million NIH Grant for Cannabinoid Analog Research
eXoZymes (EXOZ) secured a two-year, $2 million grant from the National Institutes of Health to advance cannabinoid analogs for drug discovery, with work beginning July 1, 2026.
eXoZymes () received a two-year, $2 million grant from the National Institutes of Health to develop cannabinoid analogs for pharmaceutical applications [1]. Work under the award is expected to begin July 1, 2026 [1].
The grant funds eXoZymes' efforts to expand its portfolio of proprietary new-to-nature molecules and validates the company's ability to produce rare cannabinoids and cannabinoid-like compounds [1]. The award represents the second biosolution in eXoZymes' pipeline advancing toward partnership and commercialization, following a molecule designated NCT [1].
Continue reading
2 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.